INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
GJ

Goldman Jonathan

DirectorCIK 0002013869

EDGAR filingsOpen in network
Disclosed transactions6
Buys / sells0 / 2
Max Insider Score36
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
GJ
Goldman JonathanDirector
AVTXAvalo Therapeutics, Inc.
Option exercise
M—
3,166 sh
Mar 28, 2026Mar 31, 2026
traded Mar 28, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Avalo Therapeutics, Inc.Director · Nov 17, 2025
17
GJ
Goldman JonathanDirector
AVTXAvalo Therapeutics, Inc.
Option exercise
M
—
3,166 sh
Mar 28, 2026
Mar 31, 2026
traded Mar 28, 2026
+3d
SEC FORM 4

Evidence

33
GJ
Goldman JonathanDirector
AVTXAvalo Therapeutics, Inc.
Open-market sale
SELL$45K
3,167 sh
Nov 14, 2025Nov 17, 2025
traded Nov 14, 2025
+3dSEC FORM 4

Evidence

12
GJ
Goldman JonathanDirector
AVTXAvalo Therapeutics, Inc.
Option exercise
M$81K
8,200 sh
Nov 14, 2025Nov 17, 2025
traded Nov 14, 2025
+3dSEC FORM 4

Evidence

36
GJ
Goldman JonathanDirector
AVTXAvalo Therapeutics, Inc.
Open-market sale
SELL$118K
8,200 sh
Nov 14, 2025Nov 17, 2025
traded Nov 14, 2025
+3dSEC FORM 4

Evidence

21
GJ
Goldman JonathanDirector
AVTXAvalo Therapeutics, Inc.
Option exercise
M—
8,200 sh
Nov 14, 2025Nov 17, 2025
traded Nov 14, 2025
+3dSEC FORM 4

Evidence